IES970570A2 - Glutamine enriched peptide products - Google Patents
Glutamine enriched peptide productsInfo
- Publication number
- IES970570A2 IES970570A2 IE970570A IES970570A IES970570A2 IE S970570 A2 IES970570 A2 IE S970570A2 IE 970570 A IE970570 A IE 970570A IE S970570 A IES970570 A IE S970570A IE S970570 A2 IES970570 A2 IE S970570A2
- Authority
- IE
- Ireland
- Prior art keywords
- glutamine
- peptide
- proteinase
- hydrolysates
- preparation
- Prior art date
Links
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 108091005804 Peptidases Proteins 0.000 claims abstract description 33
- 102000035195 Peptidases Human genes 0.000 claims abstract description 33
- 235000019833 protease Nutrition 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 102000004190 Enzymes Human genes 0.000 claims abstract description 25
- 108090000790 Enzymes Proteins 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 17
- 108010068370 Glutens Proteins 0.000 claims abstract description 16
- 235000021312 gluten Nutrition 0.000 claims abstract description 16
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims abstract description 14
- 229940043131 pyroglutamate Drugs 0.000 claims abstract description 14
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 12
- 239000000758 substrate Substances 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 9
- 108010061711 Gliadin Proteins 0.000 claims abstract description 7
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 3
- 108010050792 glutenin Proteins 0.000 claims abstract 2
- 239000012528 membrane Substances 0.000 claims description 10
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 6
- 108010051873 alkaline protease Proteins 0.000 claims description 4
- 230000009467 reduction Effects 0.000 abstract description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 74
- 239000000047 product Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 21
- 239000000413 hydrolysate Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229910021529 ammonia Inorganic materials 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 230000002349 favourable effect Effects 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000012901 Milli-Q water Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000012466 permeate Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000012465 retentate Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007799 cork Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079919 digestives enzyme preparation Drugs 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYAUSSKQMZRMAI-YESZJQIVSA-N (S)-fenpropimorph Chemical compound C([C@@H](C)CC=1C=CC(=CC=1)C(C)(C)C)N1C[C@H](C)O[C@H](C)C1 RYAUSSKQMZRMAI-YESZJQIVSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 101150026885 CTT-W gene Proteins 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 101710178035 Chorismate synthase 2 Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 101710152694 Cysteine synthase 2 Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108090000083 Serine Endopeptidases Proteins 0.000 description 1
- 102000003667 Serine Endopeptidases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- LGDAGYXJBDILKZ-UHFFFAOYSA-N [2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl] 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LGDAGYXJBDILKZ-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 108010007119 flavourzyme Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000013495 osmolality determination method Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
- A23J3/18—Vegetable proteins from wheat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
A glutamine-rich peptide preparation and foodstuffs containing them, the preparation having at least 28% peptide bound glutamine and a gel permeation profile with at least 90% of the peptides having a molecular weight below 3 kilodaltons. The preparation may have at least 31% peptide bound glutamine and suitably less than 1% of molecules with a molecular weight greater than 10 kilodaltons. The preparation may have less than 1.50% free pyroglutamate and shows no reduction in heat stability when heated to about 80 degrees celcius for about 10 minutes. A process for the preparation of a glutamine-enriched peptide product comprises hydrolysing a substrate selected from gluten, glutenin or gliadin. The enzyme may be Proteinase DS or Proteinase L660.
Description
Glutamine enriched peptide products
The present invention relates to a process for the preparation of a glutamine enriched peptide product and to a product produced by the process.
In general, glutamine is considered to be a non-essential nutrient as it can be synthesised by the human body. However glutamine cannot be synthesised as quickly as it is metabolised during periods of metabolic stress. There is therefore a need for glutamine in dietary preparations. Glutamine enriched products are particularly required during periods of heavy physical training. For example, it is believed that glutamine may stimulate muscle glycogen synthesis in humans so that a glutamine enriched product may have a function in restoring the muscle glycogen store after bouts of intensive physical exercise.
It is also known that in critically ill patients recovery time may be speeded up by glutamine administration. It is also believed that the immune system requires increased amounts of glutamine during stress such as infection or sepsis. Glutamine seems to have a function in helping wound repair and can improve recovery from infections generally.
Thus it is often considered that glutamine is conditionally essential.
EP-A-0 672 352 of Campina Melkunie B.V. discloses a process for the preparation of peptide mixtures having a high glutamine content in which enzymatic hydrolysis is carried out with an endopeptidase. The peptides produced by the process have peptide bound glutamine contents of up to 25%.
EP-A-0 540 462 of Sandoz Nutrition Ltd. discloses a composition containing L-glutamine of at least 20 wt%, the compositions being 35 useful in the manufacture of preparations for avoiding excessively low plasma L-glutamine levels for use in endurance exercises or other physical activities.
OPEN TO PUBLIC INSPECTION UNDER
SECTION 28 AND RULE 23 !Mi NO..
IE 970570
- 2 Glutamine-enriched peptide products are also available commercially from DMV International, Verghel, The Netherlands and Quest International, Zwijndrecht, The Netherlands.
It is thus an object of the present invention to provide a glutamine-enriched product having a high level of peptide bound glutamine and which is suitable for incorporation into dietary products such as sports formulae, food and drink products and invalid feedstuffs. The product of the present invention may also find application in injectable solutions for chronically ill patients in clinical feeding programs.
According to the present invention there is provided a glutaminerich peptide preparation having at least 28% peptide bound glutamine and a gel permeation profile with at least 90% of the peptides having a molecular weight below 3 kilodaltons. Preferably the preparation has at least 31% peptide bound glutamine, more preferably at least 37% peptide bound glutamine.
The preparation may preferably have less than 1% of molecules with a molecular weight greater than 10 kilodaltons and at least 70% of the molecules with a molecular weight of less than 1 kilodalton.
Suitably the peptide preparation has less than 1.50% free pyroglutamate.
In a particularly preferred embodiment the peptide preparation shows no reduction in heat stability when heated to about 80°C for about 10 minutes.
In a further aspect the invention provides a process for the preparation of a glutamine enriched peptide product comprising hydrolysing gluten, glutenen or gliadin with an alkaline proteinase derived from Bacillus licheniformis.
The enzymes used in the hydrolysis are preferably selected from Proteinase DS, available from Rhone Poulenc, Cheshire, U.K. and Proteinase L660, available from Solvey Enzymes, Hannover, Germany.
IE 970570
- 3 The product of the enzyme hydrolysis is then preferably filtered through membranes having cutoff values of between 5 and 30 kilodaltons (kDa), preferably between 5 and 10 kilodaltons. This serves to remove high molecular weight and undigested components.
Suitably the hydrolysate is also filtered through a 1 kilodalton membrane to remove low molecular weight material and remove free amino acids, the peptide bound glutamine content of the retentate being thus improved.
The enzyme treatment step may be carried out at between temperatures of 37° to 60°C.
The enzymes used in the hydrolysis step may be inactivated by heating the reaction mixture to at least 80°C for about 20 minutes.
Preferably the pH of the reaction mixture during enzyme treatment was kept constant. This is suitably achieved by the addition of an alkaline solution such as sodium hydroxide, using a pH titration apparatus.
Preferably, following enzyme inactivation, the reaction mixture is centrifuged, and the supernatant ultrafiItered. In a preferred embodiment the retentate is diafiItered and the permeate collected to improve yield.
The invention also relates to a foodstuff comprising a glutamineenriched peptide as defined above or whenever prepared by a process as defined above. By foodstuff is meant a solid or semi-solid food composition or beverage.
Characterisation of glutamine peptide hydrolysates
Degree of hydrolysis
The degree of hydrolysis (DH%), defined as the percentage of peptide bonds cleaved was calculated from thevolume and molarity of
IE 970570
- 4 NaOH used to maintain constant pH (Adler-Nissen, 1986). The DH% was calculated as :DH% = B(Mb)(1/alpha)(1/Mp)(l/htQt) X 100 where B is the volume of NaOH consumed (ml), Mb is the molarity of NaOH, alpha is the average degree of dissociation of the alpha-NH2 groups at pH 8.0 and 60°C (or pH 7.0 and 55°C for Proteinase L 660), Mp is the mass of protein (g), and htQt is the total number of peptide bonds in the protein substrate (mequiv/g of protein).
Protein (Nitrogen)
Total protein (N x 5.7) of substrates and hydrolysates was determined by MacroKjeldahl (IDF 20B:1993).
Protein (Nitrogen) solubility
Hydrolysates (2% w/v) were adjusted to pH 2-8 with 1 N HC1 or 1 N NaOH, stirred continuously for 1 hour and centrifuged at 1,300 g (Mistral 6000 MSE Scientific Instruments, West Sussex, UK) for 15 minutes at 20°C. The supernatants were then filtered through a Whatman No. 1 filter paper. Nitrogen was determined as described above and expressed as a percentage of total nitrogen in the hydrolysate.
(IDF 88/1:1987).
Molecular mass distribution of peptides in glutamine peptide hydrolysates
The size distribution of peptides in glutamine peptide hydrolysates was determined using a TSK 2000 SW (Beckman Instruments Ltd., UK) gel permeation column (7.5 nm x 60 cm) fitted to a Waters HPLC System. The column was eluted at a flow rate of 1 ml/min with 30% Acetonitrile containing 0.1% trifluoroacetic acid (TFA). Hydrolysates were diluted in Milli Q water to 0.25% (w/v) protein, filtered through a Whatman 0.2 yim syringe filter and 20 jjI was applied to the column. Eluate was continually assayed at 214 nm and results compared to a
IE 970570
- 5 calibration curve prepared from the average retention volume of standard proteins and peptides.
Free amino acid analysis of hydrolysates
Hydrolysates were deproteinised by mixing equal volumes of 24% (w/v) trichloroacetic acid (TCA) and sample which was allowed to stand for 10 minutes before centrifuging at 14400 g (Microcentaur, MSE, UK) for 10 minutes. Supernatants were removed and diluted with 0.2 M sodium citrate buffer, pH 2.2, to give approximately 25 nmol of each amino acid residue per 50 pi of injection volume and then analysed on a * +
120 x 4 mm cation exchange column (Na form) using a Beckman 6300 amino acid analyser (Beckman Instruments Ltd., High Wycombe UK).
Results were expressed in percentage terms, i.e. g per lOOg powder product.
Free glutamine analysis of hydrolysates
Free glutamine was measured after derivatisation with o-phthalaldehyde-mercaptoethanol (OPA-ME) and separation of the individual amino acids by means of reversed phase HPLC using a Shimadzu HPLC System (Shimadzu Corp., Analytical Instruments, Nakagyo-ku, Kyoto, Japan, Shih F.F., 1985). To a solution of 80 nmol amino acid or 24 pg hydrolysate in 0.3 ml water were added 0.2 ml OPA-ME solution. After 1 minute at room temperature, 0.5 ml 0.1 M potassium phosphate (pH 4.0) was added followed by 3.0 ml methanol. The solution was mixed, filtered through a 0.2 pm syringe filter and injected (5 pi) onto a Phenomenex (Phenomenex Ltd., Macclesfield, Cheshire, England) C^g reverse phase column (250 x 3.2 mm, 5 pm) equilibrated with solvent A (0.04 M Sodium Acetate buffer with 13.6% acetonitrile, pH 5.9-6.0). Isocratic elution was used and the flow rate was 0.3 ml/min. Eluate was continually assayed at 340 nm and results compared to microvolt (pV) responses for amino acid standards (Sigma Chemical Co. Ltd., Dorset, England). Solvent B (100% acetonitrile) was used to wash off remaining amino acids and the column was re-equilibrated with Solvent A for 15-20 minutes prior to another injection. Results were expressed in percentage terms i.e. g per lOOg powder product.
IE 970570
Free pyroglutamate analysis of hydrolysates
Free pyroglutamate (PYG) levels of glutamine peptide hydrolysates were measured by means of reversed phase HPLC using a Shimadzu HPLC System (Shih, 1985). PYG (50 nanomoles) or hydrolysates (6 pg) in 1 ml Milli Q water were mixed, filtered through a 0.2 jjm filter and injected (5 ^il) onto a Phenomenex C^ column (described above) equilibrated with solvent A (0.1% phosphoric acid). Isocratic elution was used and the flow rate was 0.3 ml/min. Eluate was continually assayed at 200 nm and the results compared to jiV responses for PYG standards (Sigma Chemical Co. Ltd., Dorset, UK). Solvent B (100% acetonitrile) was used to wash off remaining hydrolysate followed by re-equilibration with solvent A for 15-20 minutes prior to another injection. Results were expressed in percentage terms i.e. g per lOOg powder product.
Peptide bound glutamine content of hydrolysates
Peptide bound glutamine was indirectly measured by quantifying the amount of ammonia (%) released by acid hydrolysis of peptides and subsequently converting ammonia content to glutamine content (Wilcox, 1967). Glutamine peptide hydrolysate (0.1 g) was heated to 110°C in 50 ml 2 N HC1 for 3 hours. After neutralisation with potassium hydroxide (KOH), ammonia was measured enzymatically with glutamine dehydrogenase using a Boehringer ammonia detection kit (Boehringer Mannheim, East Sussex, UK). Peptides (1 g/1) were also resuspended in Milli Q water and assayed for free ammonia content. Peptide bound glutamine was calculated using the following formula %Ammoni a (After hydrolysis) %Ammonia/r. = %Ammonia (Free) (Peptide bound) %Ammon i a (Peptide bound) x 7% = %Ammonia (Attributed to Asn) %Ammonia / 17.03 x 148.13 = %Glutamine (Peptide bound)
7% of Ammonia was taken to be due to asparagine and was subtracted (Attril) to (Jin)
IE 970570
- 7 from the Ammonia ... ., to give a % Ammonia ,At) .. , ., ,,. .
(Peptide bound) (Attributed to Gin) value (MacRitchie, 1979). Results were expressed in percentage terms i.e. g per lOOg powder product.
Clarity of hydrolysate solutions
The clarity of glutamine peptide hydrolysates in solution was measured by % transmission at 600 nm on a Philips model PYE Unicam PU8610 uv/vis spectrophotometer (Philips Test and Measurement, Herts., UK).
One percent (w/v powder) solutions of hydrolysates (pH 2-8) were assayed for % transmission at 600 nm. A solution was considered clear if the transmission in a 1 cm cuvette was at least 98%.
Sensory analysis of hydrolysates
One percent (w/v protein) solutions of hydrolysates were presented to a taste panel trained to detect bitterness. Samples were compared to caffeine standards and scored (0-100%) for bitterness.
Determination of heat stability of hydrolysates
Two % (w/v) powder of various hydrolysates were heat-treated at 80°C for 10 minutes, freeze-dried and then assayed for peptide bound glutamine content as described above.
Hydrolysate osmolality determination
The osmolality of 1% (w/v) powder solutions of various hydrolysates was determined using an osmometer (Fiske & Associates, MA, USA).
Cell culture analysis
Human peripheral blood lymphocytes (PBL) were isolated by a method described by Boyum (1974) as follows. The heparin-anticoagulated blood
IE 970570
- 8 of normal subjects (buffy coat) was diluted 2-fold with PBS (pH 7.2), and PBL together with monocytes were recovered by centrifugation on Ficol1-Hypaque cushions. Cells were washed twice with 0.9% NaCl and subsequently diluted in RPM1-1640 medium containing 10% heatinactivated calf serum (Sigma, Deisenhofen, Germany) in an atmosphere containing 5% CO2· After 24 h of differentiation, PBL were separated from adherent monocytes and diluted in fresh medium for further assays.
To quantify proliferation the colorimetric Cell Proliferation ELISA (Boehringer Mannheim, Germany) was used according to manufacturer's instructions. Cells (2 x 105/200 pi) cultured in a 96-well microtiter plate in the presence of various hydrolysates were pulsed with 5-bromo-2'-deoxy-uridine (BrdU) for 12 h. Incorporation of BrdU into the DNA was detected by the anti-BrdU antibody peroxidase conjugate (POD). The amount of POD retained in the immunocomplex was quantified by a substrate reaction using TMB. Results were read out on an ELISA spectrophotometer at 450 nm (reference wavelength: 620 nm).
Commercially available glutamine-enriched peptide products were obtained from DMV International, Verghel, The Netherlands, and Quest International, Zwijndrecht, The Netherlands.
Example 1:
Assessment of a range of food protein substrates as starting material for the generation of a glutamine-enriched peptide preparation
The amino acid composition of a range of substrates was determined and the results are summarised in Table 1. From Table I it is seen that gluten and gliaden are naturally rich in glutamic acid and as such were selected as good potential substrates for the preparation of glutamine-enriched peptide hydrolysates. Wheat gluten, gliaden and β-casein were obtained from Sigma Chemical Co., (Poole, Dorset, UK), and food-grade wheat gluten was obtained from Odiums Mills Ltd., (Cork).
IE 970570
- 9 Example 2:
Assessment of commercially available enzymes for suitability for glutamine peptide hydrolysate production
The enzymes studied were selected from:Alcalase (a Serine endopeptidase [Subtilisin A] from Bacillus 1icheniformis available from Novo Nordisk, Denmark), Bioproteinase N100L (proteolytic enzyme preparation from Bacillus subtilis available from Quest International, Co. Cork, Ireland), Corolase 7092 (fungal proteinase with endopeptidase and exopeptidase activity from Aspergillus cultures available from Rohm GmbH, Darmstadt, Germany), Flavourzyme (fungal proteinase/peptidase complex from Aspergillus oryzae, available from Novo Nordisk, Bagsvaerd, Denmark), HT Proteolytic 200 (neutral proteinase [endopeptidase] from Bacillus amyloliquefaciens, available from Solvay Enzymes, Hannover, Germany), Neutrase (neutral proteinase from Bacillus subtilis, available from Novo Nordisk, Bagsvaerd, Denmark), Panazyme 77A (fungal proteinase from Aspergillus oryzae, available from Rhone Poulenc, Cheshire, United Kingdom), Profix (purified Papain extracted from the fruit Carica papaya, available from Quest International, Co. Cork, Ireland), Promod (selected proteinases from strains of Bacillus and Aspergillus combined with Papain, available from Biocatalysts, Pontypridd, Wales), Protamex (proteinase complex from Bacillus available from Novo Nordisk, Bagsvaerd, Denmark), Proteinase DS (alkaline proteinase from Bacillus 1 icheniformis, available from Rhone Poulenc, Cheshire, United Kingdom), Proteinase L 650 (alkaline proteinase from Bacillus 1icheniformis, available from Solvay Enzymes, Hannover, Germany), and Proteinase 200 (neutral proteinase from Bacillus subtilis, available from Rhone Poulenc, Cheshire, United Kingdom).
ml scale hydrolysates
2.0 g Gluten (71.51% (w/w) protein) was resuspended in 23 ml of Milli Q water in a 75 ml reaction vessel. The pH and temperature of the reaction were dictated by the enzyme under study and adjusted accordingly. Enzyme, 0.0286 g, (2% w/w protein) was mixed with 2 ml
Milli Q water and added with constant stirring to the reaction vessel.
IE 970570
- 10 The pH was kept constant by the automatic addition of 0.5 N NaOH using a pH-Stat titration apparatus (Metrohm, Herisau, Switzerland; Model 718). The reaction was allowed to proceed for 3-4 hours at which stage it was stopped by heat inactivation of the enzyme at 90°C for 20 minutes. The resulting hydrolysates were assessed for their molecular mass distribution profiles and free glutamine content. Table 2 summarises the DH% achieved and the molecular mass distributions in hydrolysates prepared at 37°C using a range of different enzymes preparations. Table 3 summarises the characteristics of gluten (Odiums) hydrolysates prepared at the optimum pH and temperature values for different enzyme preparations. This Table also includes data on the DMV and the Quest products. From the Table, it is seen that Proteinase DS and Proteinase L660 result in low levels of high molecular mass material (i.e. > 10 kDa) and high levels of low molecular mass material (i.e. < 1 kDa). These are favourable characteristics with respect to the utilisation of glutamine-enriched peptide products. Further, it is seen in Table 3 that these enzymes yield gluten hydrolysates having low levels of free glutamine and free pyroglutamate. It is evident from Table 3 that some characteristics of the 25 ml hydrolysates are more favourable than those of the DMV or Quest products.
Example 3:
Preparation of glutamine enriched peptide hydrolysates using Proteinase DS and Proteinase L660 ml/1 litre scale
Gluten (Odiums Mills Limited, Cork) was resuspended in Mi Πί Q water (8% w/v), pre-heated to 60°C (or 55°C for Proteinase L 660) and adjusted to pH 8.0 (or 7.0 for Proteinase L 660) with 0.5 N NaOH. Proteinase DS previously resuspended in water was added to the reaction mixture at a final enzyme to substrate (E/S) ratio of 1% (w/w protein). The pH was kept constant by the automatic addition of 0.5 N NaOH using a pH-stat titration apparatus (Metrohm, Herisau,
Switzerland; Model 718). The reaction was stopped after 5 hours hydrolysis by heat inactivating the enzyme at 90°C for 20 minutes.
IE 970570
- 11 The hydrolysate was cooled to room temperature, centrifuged at 2,500 g for 20 minutes, the supernatant decanted off and ultrafiltered through a 10 kDa cut off membrane (Centricon-10-membrane, Amicon, Inc. Beverly MA 01915 USA). The 10 kDa filtrate was freeze-dried.
150 litre scale (Pilot plant scale)
Gluten was reconstituted using a Silverson mixer (Machines ltd.,
Bucks., U.K.) in 150 litres of reversed osmosis (R.0.) water to give a final concentration of 8% (w/v) in a cylindrical, jacketed, stainless steel tank. Proteinase DS (or Proteinase L 660) was resuspended in R.0. water and added at a dosage rate of 1% (w/w) of the protein substrate. The reaction mixture was pre-heated to 60°C (55°C for Proteinase L 660) and maintained at pH 8.0 (pH 7.0 for Proteinase L 660) and the reaction allowed to proceed for 5 hours. The pH was maintained constant by continuous addition of 7.5 N NaOH. After 5 hours incubation the enzyme was heat inactivated at 90°C for 20 minutes. The hydrolysate was cooled to 8°C and stored overnight with gentle agitation in the jacketed stainless steel tank.
After overnight storage, the reaction mixture was heated to 25°C and centrifuged using a Westfalia (Model KNA3) centrifugal separator. The retentate was discarded and the supernatant was ultrafi1tered through a spiral wound membrane system fitted with 10 kDa nominal molecular mass cut off (Koch International (UK) Ltd., Stafford, UK).
The retentate was diafiltered with 60 litres of R.0. water and the permeates collected, evaporated and spray-dried.
The characteristics of the large-scale hydrolysates are shown in Table 4. From this Table it is seen that both enzymes produce hydrolysates with favourable characteristics i.e. having high peptide bound glutamine contents (at least 28%), low free glutamine levels, low free pyroglutamate levels, low overall free amino acid contents, favourable molecular mass distribution profiles, high solubilities, good clarity, low osmolality and hydrolysates displaying good heat and acid stabilities. Similar results were obtained for the small scale (25 ml) hydrolysates (data not shown).
IE 970570
- 12 Example 4:
Enrichment of Proteinase DS and L660 gluten hydrolysates for peptide bound glutamine content
Ten grams of glutamine peptide hydrolysate was resuspended in 200 ml of Milli Q water. The 5% (w/v) solution was filtered through an Amicon stirred cell unit (model 202) (Amicon, Inc. Gloustershire, UK) fitted with a YMI (1 kDa nominal molecular mass cut off) Diaflo ultrafiltration membrane (Amicon, Inc. Gloustershire, UK) until 60-70 ml of permeate (equivalent to 15-20% by weight of hydrolysate) was collected. Both retentate and permeate solutions were freeze dried and their peptide bound glutamine contents determined.
Table 5 summarised the characteristics of the retentates obtained from the above procedure. Using this procedure it is seen that the peptide bound glutamine content of the hydrolysates can be increased to > 30%. Furthermore, favourable reductions in osmolality, free amino acids, free glutamine and free pyroglutamate were achieved using the above ultrafiltration step (see Table 4).
Example 5:
Generation of glutamine-enriched hydrolysates from gliaden
Proteinase DS and L560 hydrolysates of gliaden were prepared at 25 ml scale using the procedure as outlined in Example 3. The characteristics of the resulting products are outlined in Table 6.
Both products contain high levels of peptide bound glutamine (37%), low free glutamine levels, low free pyroglutamate levels, low overall free amino acid contents, favourable molecular mass distribution profiles, high solubilities, good clarity, low osmolality and hydrolysates displaying good heat and acid stabilities. It is evident therefore that the gliadin hydrolysates have superior characteristics to the DMV and Quest products.
IE 970570
- 13 Example 6:
Enrichment of proteinase DS and L660 gliadin hydrolysates for peptide bound glutamine content
Ten grams of glutamine peptide hydrolysate(s) from Example 5 was resuspended in 200 ml of Mi 11i Q water. The 5% (w/v) solution was filtered through an Amicon stirred cell unit (model 202) (Amicon, Inc. Gloucesterhire, UK) fitted with a YM1 (lkDa nominal molecular mass cut off) Diaflo ultrafiltration membrane (Amicon, Inc. Gloucestershire, UK) until 60-70 ml of permeate (equivalent to 15-20% by weight of hydrolysate) was collected. Both retentate and permeate solutions were freeze dried and their peptide bound glutamine contents determined. Table 7 summarises the characteristics of the retentates obtained from the above procedure. Using this procedure it is seen that the peptide bound glutamine content of the hydrolysates can be increased to >37.5%. Furthermore, favourable reductions in free amino acid, free glutamine and free pyroglutamate levels were achieved using the above ultrafiltration step.
Example 7
Tissue culture analysis of glutamine-enriched peptide hydrolysates
It can be seen from Figure 1 that the glutamine rich peptide products (OGDS and 0GL660) described herein (Table 4) bring about significant increases in the proliferative response of concanavalin A-activated peripheral blood cells. It is also seen that these hydrolysates mediate greater proliferative responses than the commercially available glutamine-enriched peptide products (Figure 1).
It is evident from the preceding examples that novel glutamine rich peptide products have been produced which have improved/high peptide bound glutamine contents, favourable molecular mass distribution profiles, low levels of free amino acids, low free glutamine levels, low pyroglutamate levels, high solubilities, good clarity, good heat and acid stabilities, low osmolalities and high peripheral blood lymphocyte stimulating abilities. The osmolality
IE 970570
- 14 values of the different glutamine rich products are summarised in Appendix 1.
References
Adler-Nissen J. (1986). Enzymatic hydrolysis of food proteins.
Elsevier Applied Science, Publishers, London.
Boyum A. (1974). Tissue Antigens 4, 269.
International Dairy Federation Cicrulaire; 88/1; October 1987.
International Dairy Federation Cicrulaire; 20B; 1993.
MacRitchie F. (1979). A relation between gluten protein amide content and baking performance of wheat flours. Journal of Food Technology 14: 595-601.
Shih F.F. (1985) Analysis of glutamine, glutamic acid and pyroglutamic acid in protein hydrolysates in high performance liquid chromatography. Journal of Chromatography, 322: 248-256.
Wilcox P.E. (1967). Determination of amide residues by chemical methods. In: Methods of Enzymology. Academy Press Publishers, New York.
- 15 IE 970570 a
»»« ci) ¢5
E «3 © cm co © cx it, —
CM r-i
CM ao oo © οχ χτ — - - - © ©
Ό r(-c·. cm cm © k i*i c ts 7 c cm’ cm cm © © © cm τ V ©
— © o r~ © ι-- © mo © o — rcM n — 05
CM © CM — CM inr'<->C\t~'f^cMOOiOr^CM—CMr^O~ r-i©xTOO©CM©0£>Ooxf'-oc<'X©i/x©eo 06 ©’ CM ©’ ox’ cm’ oo O © © © 00 © OX yT © © cm tt oc cm CM vx cm ox ox χτ
XT xj- Γ- © m CM — rx
T5
O ej
P.
« oj
4J e
S κ
To έ
ο
m O\ © νΛ Cx © CM ΙΛ CM © «— XT 00 CM X—· CM © © r-' © © © xr © © © © 00 Tf- *n © o' o cK tr © o' © «η CM W*l oo Xt «9 «— XT ©' © CM CM CM CM © CM CM M* Cx CM VO CM cr
Ml «ϊ
Ξ bfi
© tn © CM rr © tn cx ΓΊ © 00 o r—» CM rr xT m CM TT in © c- © tn © r~~ © © «η tn Γ c< 0© r* CM 00 CM © 00 60 eM >T © © © CM © Cx CM rr CM rr CM CM tn cr CM ΤΓ xt co © © CM *** xj·
«3
Table 1: Amino ncid composition of a range of food protein .substrates.
I· rr © r- © tn co © rr CM CM CM CM © Cx © S t*- GO •M- © 'M' © tr cr 00 00 00 © cr tn Cl to o © cr © XT 00 CM cr ©' tri oi © oO 00 o es Ό CM rr χτ tri xr XT © XT 00 cr © CM © 00 s CM «? © >* cn co Tf © © w—. © in oc © CM © Xt CM © tn © © o o γ- CM vo tr © 00 r- rr CM © cr *— © © oe o' o CO o tn co © CM XT © o' CM CM s o \C tr CT χΤ XT © «η CM cr © cr tC CM u CM ©L © © © © o © o © o O © © © © © © © © CM o CM *n 00 CM rr vo ’—1 © oo Ό «—R CM CM XT o O tn CM , c © cr CM cr © rr CM © — c © © vo © XT cr CM © © Γ- cr XT TT CM -cr
>>
ο ο
C
L.
Ρ.
Μ
Ξ
Έ <
ο e
ε
Τ3
ΓΞ '5 3 <
ο
C ο
.C
α.
ί>
C *
•σ 'ο <
ο
© .£ .2 ‘-Ρ o i S ΙΞ c § © c O < S u~ •c L·. c- ί © CZ3
ο
C ο ο C C & S
«- # © © c © s ‘3 □ a c qj © © c ’© _c '3 Z3 c *53 O u. si >. C V c 72 C/3 © .£ ‘55 ’2 'So >> w > © CO © >. t- A. SE t-3 x5
Glutamine is converted to glutamic acid during acid hydrolysis * Cysteine is converted to cysteic acid during acid hydrolysis
- 16 IE 970570
Table 2: Degree of hydrolysis (DB %) achieved and molecular mnss distributions of gluten (Sigma) hydrolysntes prepared nt 37° C with a range of commercially available enzymes.
Values expressed as% total area for a gel permeation profile obtained at 214 nm
IE 970570
- 17 Table 3: Characteristics of hydrolysates prepared with gluten (Odiums) using a range of commercially available enzyme preparations.
r- r- © © © m cr r· cn © ©s s <3 \o © Ό oo cs Cl m ·· m art © VO t) Q Ό © 00* s cn © cs —* I-M rS CS 2 CS cs C- m CS s o Λ <; © ·© CS o m, cs r- — oc © Γ- ·—* © ”?r in o © ΙΖΊ B z z 00 OS* ΓΊ © cn © oc wn oc o-’ e '•w·' < < Ό T © cn © © — cs C- © i/n VO vn cs vn z z cs' n — cs —- fS rs OS rs CS
zn ε
e.
S cs •o
CJ c
o «ϋ o
u.
c.
ϋ c
c
>
o to ¢3 •s ε
¢ε >,
EC
E >s
N
P fid
O 0
KV V*.
οο _o ©
•ZV ©
oo w
{<
γ©
Γ- ©
oc ©
C-’
<
γγο
E oc
CCS
TJ o
£ ©
c o
·-» ©
£ w
n §
e
V© cr*· tn
Έ tn
Q u_
Cta ©
Cv>
© _2
-*z
II
Not determined
IE 970570
M O OC © — 1 J © c· VT WT rs © CT © © o s© 00 CM © © ci © 60 M5 CT CT 60 © CT Ci CM T CM
u c
ε
Ti g
σ i
cc CM
V cr
I r- 04 ε 2
Λ * oo ©
cm c,
WT to
c σ
ϋ §
lOO ©
©
CM ©
©
CM ©
© ©
t*· — ©
CM © m± CT cs c*c ©
o9 ©
c.
5Γ
© CT \© 00 *T 2 Cr x« Μί* 00 © 1 CM c« X <© Q. xp CT 1 CM © s Λ ©. 0 00 © Λ
C β
g ¢5 <£
S © z
WT ©
Tabic 4: Comparative characteristics of large scale glutamine enriched hydrolysate products.
© o’ r© o’
CM
CT
CM
MT CM ©
— S ©
MT
Sfi o
o
Mf *Λ © CM © MT CM CT 'C mT © MT CT © oe © © r- © CM CM
r~ co
S rCZ3 fi o
c to
Ί3 c
,£
I o
c c
© uU0s· o
•o cs
E tfl
E to o
E o
'i
X re
S=
S &
tx. ¢=I
CL.
_re o
E
JS
S jy
Σ
© OO □0 e ’g « 1 CM 1 CM x a X X C- c. © s .2 o © 2 © © Λ 00 © A © z
c
Z
E o
x o
o ©
oc s
s mT
CM
4-J
C3
Έ
-Ξ
-O o
tC o
c .2 s
© \©
Q o o W1 vi co C3 C .£ *© 3 75 ο Λ£ ~ £
Z? -ζ o
a.
© to eC
O
-hi ©
<0 <3 LS « ίΞ co C Q Q •ft r> ΐπ tn □ •c Έ 3 CT -W *o «Q o δ O V V CZ) CJ -< X
-rt U © v> vj >T •5 2 S -S >> § Έ >x -C ιλ C e g - £ £ = fr « -Ξ cii δ 4>. “ a 3 1 § 2 ? ϊ Q
0s
IE 970570
-IDTable 5 : Characteristics of glutamine enriched hydrolysates following ultrafiltration through 1 kDa cut off membranes
'S £
(Π o
>>
Values expressed as % total area for a gel permeation profile obtained at 214 nm ) = Not determined s
O
Vs © Q tn
-S O v
4—» o 2
Q.
-1 if s 1 Έ ao >* .S *3
E -S S o c J= o •S -a
Si ? n a e = § δ ©
e. o co Ό v© «η n
σ O E O
Ό ©
VI «
£
IE 970570
- 20 Table 6: Characteristics of gliadin hydrolysates
ε c
''T
CS cc *σ ζ
'rt o
j» u;
c
u.
Q.
Not determined
IE 970570
-21Table 7: Characteristics of gliadin glutamine enriched hydrolysates following ultrafiltration through 1 kDn cut off membranes *5
TJ c
O _o ©
Oo g
u 'C cs ©
s
Έ oo o
-O
S-I
CL.
(Zl ft
C
ΓΊ o w> O o o W> o OO —- σ W) cn o’ W> <1 © OO cn CM o
'T o' oo .= a
o
C*· »-*
CM O CM
CM C* w-’ 00
Cs CM W> m tn
CM 0 00 ’’T O © Wl OO c o’ o OO WI ·£ m co Λ
Ίϊ
a o <3 © 04 O .5 E ¢3 § c S 3 J3 S 3 £ <3 So o 2 cx c 1 taj Ό 2 o. -» .s o .S o o x> ©
Vi o
o x= e>
xP o>
X>
V]
VI
-33 2
Έ .5
J3
O c
_o
4—»
C5
O ε
to
Not determined
T3 ©
g· ©
(Λ
V
J3 >
♦ ♦
co a
o ©
ha a
·§ S S
Lr ha W
c.
u
Pα'χ
JS o
E tn o
CJ ft
970570
-22Appendix ϊ
Summary table of osmolality values for glutamine peptide hydrolysates
Test sample Osmolality (mOsm/kg) DMV 34 Quest 28 OGDS 20 OGL660 18 Ultrafiltrated Odiums gluten/Proteinase DS 17 Ultrafiltrated Odiums gluten/Proteinase L660 15 GDS 28 GL660 26
Ο ® 5 17
Claims (5)
1. A glutamine-rich peptide preparation having at least 28%, preferably at least 31%, most preferably at least 37% peptide bound glutamine, and a gel permeation profile with at least 90% of the peptides having a molecular weight below 3 kilodaltons and preferably at least 70% of the molecules with a molecular weight of less than 1 kilodalton, and preferably less than 1% of molecules with a molecular weight greater than 10 kilodaltons.
2. A glutamine-rich peptide preparation as claimed in claim 1 having less than 1.50% free pyroglutamate.
3. A process for the preparation of a glutamine-enriched peptide product comprising hydrolysing a substrate selected from gluten, glutenin or gliadin with an alkaline proteinase derived from Bacillus 1 ichertiformis, the enzyme preferably being selected from Proteinase DS or Proteinase L660, and preferably the product of enzyme hydrolyis being filtered through membranes having cut-off values of between 5 and 30 kilodaltons, preferably between 5 and 10 kilodaltons.
4. A glutamine-rich peptide preparation substantially as described herein with reference to the Examples.
5. A food-stuff comprising a glutamine-rich peptide preparation as claimed in claim 1 or claim 2 or claim 4, or a peptide preparation whenever prepared by a process as claimed in claim 3.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE970570 IES80880B2 (en) | 1997-07-31 | 1997-07-31 | Glutamine enriched peptide products |
| AU86437/98A AU8643798A (en) | 1997-07-31 | 1998-07-31 | Glutamine enriched peptide products |
| PCT/IE1998/000068 WO1999005918A1 (en) | 1997-07-31 | 1998-07-31 | Glutamine enriched peptide products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE970570 IES80880B2 (en) | 1997-07-31 | 1997-07-31 | Glutamine enriched peptide products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IES970570A2 true IES970570A2 (en) | 1999-01-10 |
| IES80880B2 IES80880B2 (en) | 1999-05-05 |
Family
ID=11041555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE970570 IES80880B2 (en) | 1997-07-31 | 1997-07-31 | Glutamine enriched peptide products |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU8643798A (en) |
| IE (1) | IES80880B2 (en) |
| WO (1) | WO1999005918A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703208B1 (en) * | 1999-10-20 | 2004-03-09 | Immco Diagnostics | Immunological assay for detection of antibodies in celiac disease |
| EP1224869B1 (en) * | 2001-01-12 | 2004-09-22 | Campina B.V. | Method for producing a gluten-free peptide preparation and preparation thus obtained |
| TWI351278B (en) * | 2002-03-01 | 2011-11-01 | Nisshin Pharma Inc | Agent for preventing and treating of liver disease |
| ATE538660T1 (en) * | 2008-06-03 | 2012-01-15 | Novozymes As | METHOD FOR PRODUCING A WHEAT PROTEIN HYDROLYZATE |
| AU2009254004B2 (en) | 2008-06-03 | 2015-01-22 | Novozymes A/S | Method for producing a casein hydrolysate |
| DE102012205372A1 (en) * | 2012-04-02 | 2013-10-02 | Evonik Industries Ag | Glutamine-rich peptides as air-entraining agents in building material |
| CN114982861A (en) * | 2022-06-16 | 2022-09-02 | 西南大学 | Thick sensory peptide and preparation method and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991013554A1 (en) * | 1990-03-09 | 1991-09-19 | Novo Nordisk A/S | Protein hydrolysates |
| GB9121467D0 (en) * | 1991-10-10 | 1991-11-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| JP2524551B2 (en) * | 1992-02-28 | 1996-08-14 | 雪印乳業株式会社 | Peptide composition having high glutamine content, method for producing the same, and enteral nutritional supplement |
| EP0634168A1 (en) * | 1993-01-29 | 1995-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Nutritive composition |
| JP3202093B2 (en) * | 1993-02-26 | 2001-08-27 | 株式会社日清製粉グループ本社 | Oligopeptide mixture and method for producing the same |
| NL9400418A (en) * | 1994-03-16 | 1995-11-01 | Campina Melkunie Bv | Processes for the preparation of glutamine-rich peptides and nutritional preparations made therewith. |
| EP0845974A1 (en) * | 1995-08-23 | 1998-06-10 | Quest International B.V. | Compositions containing a peptide cell growth promoter |
-
1997
- 1997-07-31 IE IE970570 patent/IES80880B2/en not_active IP Right Cessation
-
1998
- 1998-07-31 WO PCT/IE1998/000068 patent/WO1999005918A1/en active Application Filing
- 1998-07-31 AU AU86437/98A patent/AU8643798A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU8643798A (en) | 1999-02-22 |
| IES80880B2 (en) | 1999-05-05 |
| WO1999005918A1 (en) | 1999-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6395508B1 (en) | Peptide mixture and products thereof | |
| ES2359789T3 (en) | PROTEIN HYDROLYZED IMPROVED BIOACTIVE SUERO. | |
| Hernández-Ledesma et al. | Release of angiotensin converting enzyme-inhibitory peptides by simulated gastrointestinal digestion of infant formulas | |
| US5744179A (en) | Low-phosphorus whey protein, manufacturing method thereof, low-phosphorus purified whey hydrolysate and manufacturing method thereof | |
| NO320644B1 (en) | Bioactive hydrolyzate of whey protein, process for its preparation, and products thereof. | |
| EP0785726B1 (en) | Method for production of a milk protein hydrolyzate | |
| US10172375B2 (en) | Compositions comprising carbohydrates and peptides which comprise tryptophan | |
| IES970570A2 (en) | Glutamine enriched peptide products | |
| US6372452B1 (en) | Process for obtaining plant peptones with a high hydrolysis degree and applications thereof | |
| US20190239538A1 (en) | Method for producing whey protein hydrolysate having superior flavor | |
| JP2004081192A (en) | Method for producing milk protein hydrolyzate with reduced odor and milk protein hydrolyzate | |
| JPH0898656A (en) | Whey protein peptide composition and its production | |
| NL8304449A (en) | PROCESS FOR THE PREPARATION OF HYDROLYSIS PRODUCTS OF PROTEINS. | |
| JP7252733B2 (en) | Method for producing milk protein hydrolyzate | |
| AU2022353630A1 (en) | Method for producing peptide | |
| JP3636322B2 (en) | Whey protein hydrolyzate and method for producing the same | |
| JP2959747B2 (en) | Savory whey protein hydrolyzate and method for producing the same | |
| JPH0678685A (en) | Production of protein hydrolyzate without unpleasant taste | |
| JPH10271958A (en) | Method for producing protein hydrolyzate with reduced odor | |
| KR102868974B1 (en) | Low MW soy protein isolate improved on sensual bitter, fishy taste and digestibility, and preparation method of the same | |
| AU701507B2 (en) | Peptide mixture and products thereof | |
| JPH08140693A (en) | Method for producing peptide mixture with low phenylalanine content | |
| WO2025047598A1 (en) | Method for producing peptide, composition containing peptide, and food/beverage using same | |
| JPH05344847A (en) | Low antigenic decomposed protein free from disagreeable taste and its production | |
| KR20200124053A (en) | Low MW soy protein isolate improved on sensual bitter, fishy taste and digestibility, and preparation method of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed | ||
| NE4A | Application for restoration sect. 37 patents act 1992 | ||
| MK9A | Patent expired |